Farmak has launched a new prescription medicinal product — a daytime tranquilizer developed to support patients with anxiety and asthenic conditions. This is already the company’s third new product introduced in 2026.
The product is indicated for the treatment of neurotic and psychopathic asthenia, conditions accompanied by anxiety and fear (including before surgical interventions or painful diagnostic procedures), as well as increased irritability, emotional lability (emotional instability), and sleep disturbances. In addition, the product is used as part of combination therapy to reduce withdrawal symptoms and as maintenance therapy during remission in alcoholism, as well as for stuttering and migraine.
The medicinal product is the first generic medicine on the market. The active pharmaceutical ingredient (API) is manufactured at Farmak’s own facilities, ensuring full quality control at every stage of production. The product is available in tablet form and has undergone two clinical studies confirming its bioequivalence to the original medicinal product.
According to a study conducted within the framework of the nationwide mental health program How Are You? (2025), 47% of Ukrainians experience high or elevated levels of stress. This highlights the growing need for accessible, effective, and high-quality therapy under current conditions.
Farmak continues to actively expand its product portfolio, launching around 20 new medicinal products to the market each year in response to the evolving needs of the healthcare system. Today, the company’s portfolio includes more than 450 medicinal products, while its export geography covers over 60 countries worldwide
